Oestrogen receptors α and β show different associations to clinicopathological parameters and their co-expression might predict a better response to endocrine treatment in breast cancer

S Borgquist; C Holm; M Stendahl; L Anagnostaki; G Landberg; K Jirström

doi:10.1136/jcp.2006.040378

Responses

Original article

Oestrogen receptors α and β show different associations to clinicopathological parameters and their co-expression might predict a better response to endocrine treatment in breast cancer

Compose a Response to This Article

Compose Response

Title *

Author Information

Contributors
First Name and Middle Initial * First or given name, e.g. 'Peter'. Last Name * Your last, or family, name, e.g. 'MacMoody'. Email Address * Your email address, e.g. higgs-boson@gmail.com Occupation * Your role and/or occupation, e.g. 'Orthopedic Surgeon'. Affiliation * Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.

Statement of Competing Interests

Competing interests? *

Yes

Please describe the competing interests

PLEASE NOTE:

A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses.
We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
By submitting this rapid response you are agreeing to our terms and conditions for rapid responses and understand that your personal data will be processed in accordance with those terms and our privacy notice.

I agree to and have read the terms and conditions for rapid responses and BMJ Privacy Notice *

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

Jump to comment:

Estrogen receptor beta immunohistochemistry: time to get it right
Valerie Speirs
Published on: 18 April 2016

Published on: 18 April 2016
Estrogen receptor beta immunohistochemistry: time to get it right
- Valerie Speirs, Senior lecturer
- Other Contributors:
  Caroline A. Green, and Abeer M. Shaaban
Dear Editor
We read with interest the paper by Borgquist et al (2008), published recently in Journal of Clinical Pathology¹. In their article the authors aimed to investigate the impact of ERbeta expression on breast cancer outcome using a cohort of 512 tumours represented in tissue microarray (TMA). Since the discovery of ERbeta over a decade ago, this has been the goal of many research groups. However pr...
Show More

Dear Editor
We read with interest the paper by Borgquist et al (2008), published recently in Journal of Clinical Pathology¹. In their article the authors aimed to investigate the impact of ERbeta expression on breast cancer outcome using a cohort of 512 tumours represented in tissue microarray (TMA). Since the discovery of ERbeta over a decade ago, this has been the goal of many research groups. However progress in this area has been impeded by the lack of a consensus in terms of choice of primary antibody and cut-off value used to determine ERbets postivity^2,3. Additionally, we know that ERbeta exists as 5 isoforms (ERbeta1-5), each formed by alternative splicing of the last coding exon^4,5, which has further complicated interpretation of immunohistochemical studies. Comparative studies have been conducted to help determine the most suitable antibody for a number of applications and of these, 2 reliable antibodies have emerged for immunohistochemistry: 14C8 (AbCam, Cambridge, UK), located in the N-terminus of the ERbeta peptide and which detects most isoforms of ERbeta and PPG5/10 (Serotec, Oxford, UK) which is specific for ERbeta1^2,6,7. We routinely use both these antibodies in our immunohistochemical studies. Borgquist et al¹ used a different antibody, EMR02 (Novocastra, Newcastle-upon-Tyne), which is claimed through epitope mapping studies to show specific reactivity to a 17-amino acid sequence present in the C-terminus of full length wild type ERbeta and which is absent in ERbeta2/ERbetacx 8. While Borgquist et al¹ show immunohistochemical and Western blot analysis of ERbeta in a panel of breast cell lines we find it remarkable that they showed no staining of their breast TMAs especially as all the survival data presented in the paper was obtained from these. Using cell lines to validate antibodies is certainly a step in the right direction but it is insufficient as tissue characteristics and processing protocols will almost certainly differ substantially from those used in cell lines and these may alter antibody specificity and sensitivity.
In addition, the authors used a very low cut off value to define ERbeta positivity (1%) and with such a value we find it surprising that the percentage of ERbeta positive tumours was only 50% - substantially less than in many previous studies^6,9-12. We believe this could indicate an issue with antibody specificity and suggest this be confirmed through peptide absorption studies.
Finally, as part of or on-going programme to understand the significance of ERbeta in breast carcinogenesis, when EMR02 antibody became available, we compared its efficacy to the well-validated 14C8 and PPG5/10 antibodies which we use routinely. As illustrated in Figure 1, we were unable to achieve robust and consistent staining using EMR02, while TMA and full sections of breast carcinoma were clearly stained with 14C8 and PPG5/10.
Figure 1 - Serial sections of TMAs (top panel) and full sections (bottom panel) of breast carcinomas stained with EMR02 (a, d), 14C8 (b, e) and PPG5/10 (c, f). Consistent staining was only observed for 14C8 and PPG5/10 with EMR02 unable to detect the protein.
There still remains a great deal of controversy and indeed suspicion surrounding the potential importance of ERbeta in breast cancer. We believe to a large extent this is due to the use of poorly validated antibodies which have poisoned the field somewhat. We urge all scientists, clinicians and journals to be aware of the need for carefully validated studies to help eliminate these controversies which, more than a decade on, still continue to cloud ERbeta.
Valerie Speirs
References
1. Borgquist S, Holm C, Stendahl M, et al. Oestrogen receptors alpha and beta show different associations to clinicopathological parameters and their co-expression might predict a better response to endocrine treatment in breast cancer. J Clin Pathol 2008;61:197-3.
2. Carder PJ, Murphy CE, Dervan P, et al. A multi-centre investigation towards reaching a consensus on the immunohistochemical detection of ERbeta in archival formalin-fixed paraffin embedded human breast tissue. Breast Cancer Res Treat 2005;92:287-93.
3. Shaaban AM, Speirs V. Estrogen receptor beta - which one and where should we draw the line? Hum Pathol 2006;37:498.
4. Moore JT, McKee DD, Slentz-Kesler K, et al. Cloning and characterization of human estrogen receptor beta isoforms. Biochem Biophys Res Commun 1998;247:75-8.
5. Poola I, Abraham J, Baldwin K, et al. Estrogen receptors beta4 and beta5 are full length functionally distinct ERbeta isoforms: cloning from human ovary and functional characterization. Endocrine 2005;27:227-38.
6. Skliris GP, Parkes AT, Limer JL, et al. Evaluation of seven oestrogen receptor beta antibodies for immunohistochemistry, western blotting, and flow cytometry in human breast tissue. J Pathol 2002;197:155-62.
7. Weitsman GE, Skliris G, Ung K, et al. Assessment of multiple different estrogen receptor-beta antibodies for their ability to immunoprecipitate under chromatin immunoprecipitation conditions. Breast Cancer Res Treat 2006;100:23-31.
8. Rees ML, Marshall I, McIntosh GG, et al. Wild-type estrogen receptor beta expression in normal and neoplastic paraffin-embedded tissues. Hybrid Hybridomics 2004;23:11-8.
9. Saunders PT, Millar MR, Williams K, et al. Expression of oestrogen receptor beta (ERbeta1) protein in human breast cancer biopsies. Br J Cancer 2002;86:250-6.
10. Shaaban AM, O'Neill PA, Davies MP, et al. Declining estrogen receptor- beta expression defines malignant progression of human breast neoplasia. Am J Surg Pathol 2003;27:1502-12.
11. Fuqua SA, Schiff R, Parra I, et al. Estrogen receptor beta protein in human breast cancer: correlation with clinical tumour parameters. Cancer Res 2003;63:2343-39.
12. Nakopoulou L, Lazaris AC, Panayotopoulou, et al. The favourable prognostic value of oestrogen receptor beta immunohistochemical expression in breast cancer. J Clin Path 2004;57:523-28.
Show Less

Conflict of Interest:
None declared.
- Back to top

Main menu

Plain text

PLEASE NOTE:

Vertical Tabs

Other responses

Jump to comment:

Log in using your username and password

Main menu

Log in using your username and password

You are here

Plain text

PLEASE NOTE:

Vertical Tabs

Other responses

Jump to comment:

Read the full text or download the PDF:

Log in using your username and password